Expanding and Underscoring the Hepato‐Encephalopathic Phenotype of QIL1/MIC13

Bianca E. Russell, Kaitlin G. Whaley, Kevin E. Bove, Anatalia Labilloy, Rachel C. Lombardo, Robert J. Hopkin, Nancy D. Leslie, Carlos Prada, Zahra Assouline, Giulia Barcia, Juliette Bouchereau, Maryline Chomton, Dominique Debray, Imen Dorboz, Philippe Durand, Pauline Gaignard, Dalila Habes, Claude Jardel, François Labarthe, Jonathan Lévy, Anne Lombès, Claire Mehler‐Jacob, Judith Melki, Laura Menvielle, Arnold Munnich, Charlotte Mussini, Samia Pichard, Marlène Rio, Agnès Rötig, Samira Sissaoui, Abdelhamid Slama, Alexander G Miethke, Manuel Schiff – 26 March 2019

Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14‐Day Waitlist Mortality Than Status‐1a Patients

Vinay Sundaram, Parth Shah, Robert J. Wong, Constantine J. Karvellas, Brett E. Fortune, Nadim Mahmud, Alexander Kuo, Rajiv Jalan – 25 March 2019 – Patients listed for liver transplantation (LT) as status 1a currently receive the highest priority on the waiting list. The presence of acute on chronic liver failure (ACLF) with three or more organs failing (ACLF‐3) portends low survival without transplantation, which may not be reflected by the Model for End‐Stage Liver Disease‐Sodium (MELD‐Na) score.

Impact of Chronic Kidney Disease on Outcomes in Cirrhosis

Florence Wong, K. Rajender Reddy, Jacqueline G. O’Leary, Puneeta Tandon, Scott W. Biggins, Guadalupe Garcia‐Tsao, Benedict J. Maliakkal, Jennifer C. Lai, Michael B. Fallon, Hugo E. Vargas, Ram Subramanian, Paul J. Thuluvath, Patrick S. Kamath, Leroy Thacker, Jasmohan S. Bajaj – 25 March 2019 – We hypothesize that the prevalence of chronic kidney disease (CKD) among patients with cirrhosis has increased due to the increased prevalence of CKD‐associated comorbidities, such as diabetes.

Telemedicine: An Evolving Field in Hepatology

Cindy Piao, Norah A. Terrault, Souvik Sarkar – 25 March 2019 – Healthcare delivery has been dramatically changing in recent times with advances in technology. One area of expansion has been the use of telemedicine due to progression in communication technologies. Telemedicine offers the opportunity to overcome barriers of access, improve patient satisfaction, improve healthcare outcomes and streamline communication between patients and providers.

Lipocalin‐2 Protects Against Diet‐Induced Nonalcoholic Fatty Liver Disease by Targeting Hepatocytes

Yanyong Xu, Yingdong Zhu, Kavita Jadhav, Yuanyuan Li, Huihui Sun, Liya Yin, Takhar Kasumov, Xiaoli Chen, Yanqiao Zhang – 25 March 2019 – Hepatocytes are the major source of hepatic lipocalin‐2 (LCN2), which is up‐regulated in response to inflammation, injury, or metabolic stress. So far, the role of hepatocyte‐derived LCN2 in the development of nonalcoholic fatty liver disease (NAFLD) remains unknown.

Correlation of Immune Markers With Outcomes in Biliary Atresia Following Intravenous Immunoglobulin Therapy

Sehee Kim, Jeffrey Moore, Estella Alonso, Joseph Bednarek, Jorge A. Bezerra, Catherine Goodhue, Saul J. Karpen, Kathleen M. Loomes, John C. Magee, Vicky L. Ng, Averell H. Sherker, Caroline Smith, Cathie Spino, Veena Venkat, Kasper Wang, Ronald J. Sokol, Cara L. Mack, The Childhood Liver Disease Research Network – 25 March 2019 – Biliary atresia is a progressive fibroinflammatory cholangiopathy of infancy that is associated with activation of innate and adaptive immune responses targeting bile ducts.

Association Between Institutional Factors and Long‐Term Survival Following Transjugular Intrahepatic Portosystemic Shunt

Jeffrey M. Mah, Yvonne DeWit, Maya Djerboua, Alexandre Menard, Christopher M. Booth, Jennifer A. Flemming – 25 March 2019 – Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure designed to treat portal hypertension. Hospital teaching status is an institutional factor found to be predictive of outcomes following several complex procedures; however, its impact on outcomes following TIPS is unknown. The aim of this study was to determine the association between hospital teaching status and long‐term survival in patients with cirrhosis receiving TIPS.

Antegrade Hepatic Artery and Portal Vein Perfusion Versus Portal Vein Perfusion Alone in Living Donor Liver Transplantation: A Randomized Trial

Johns Shaji Mathew, K.Y. Santosh Kumar, Krishnanunni Nair, Binoj Sivasankara Pillai Thankamony Amma, Lakshmi Krishnakumar, Dinesh Balakrishnan, Unnikrishnan Gopalakrishnan, Ramachandran Narayana Menon, Aleena Sunny, Puneet Dhar, Sudheer Othiyil Vayoth, Sudhindran Surendran – 25 March 2019 – Traditionally, deceased donor liver grafts receive dual perfusion (DP) through the portal vein and the hepatic artery (HA) either in situ or on the back table. HA perfusion is avoided in living donor liver grafts for fear of damage to the intima and consequent risk of hepatic artery thrombosis (HAT).

A 17‐Beta‐Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease

Jie Yang, Eric Trépo, Pierre Nahon, Qian Cao, Christophe Moreno, Eric Letouzé, Sandrine Imbeaud, Quentin Bayard, Thierry Gustot, Jacques Deviere, Paulette Bioulac‐Sage, Julien Calderaro, Nathalie Ganne‐Carrié, Alexis Laurent, Jean Frédéric Blanc, Erwan Guyot, Angela Sutton, Marianne Ziol, Jessica Zucman‐Rossi, Jean‐Charles Nault – 25 March 2019 – Recently, a loss of function variant (rs72613567) in 17‐beta‐hydroxysteroid dehydrogenase 13 (HSD17B13) has been identified as protective of nonalcoholic (NAFLD) and alcoholic liver disease (ALD).

Subscribe to